Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched Targeted Therapy Based on Biomarkers Identified by ctDNA Genotyping By Ogkologos - November 11, 2024 600 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SCRUM-Japan GOZILA study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection October 2, 2024 Survival According Circulating Tumour DNA Status in the Study of Adjuvant... December 10, 2020 EMA Grants a Marketing Authorisation for Two Biosimilar Medicines, Bevacizumab February 15, 2021 EMA Recommends Extension of Indications for Venetoclax May 14, 2021 Load more HOT NEWS Improving cancer care for the LGBTQ+ community What to Know About 3 Common Misconceptions Around Food and Cancer... Staging at Presentation for Patients with Localised Pancreatic Ductal Adenocarcinoma Should... Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After...
